Seraphim Space Investment Trust (LSE: SSIT) leans on ICEYE re-rating and SpaceX IPO tailwind to consolidate FTSE 250 entry
Read More Pharma Industry News What REYOBIQ’s Phase 1 data means for the future of CNS-directed radiopharmaceutical platforms What does REYOBIQ’s Phase 1 data reveal about the future of CNS-targeted radiopharmaceuticals? Explore the broader neuro-oncology implications. bySoujanya RaviMay 10, 2026